Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Paris: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

Chronic urticaria occurs in about 0.1% of the population (Greaves, 2000). Patients previously classified as having chronic idiopathic or "ordinary" urticaria are now divided into two groups ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain ...

“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives,” said ...

Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older. Several studies reported reduced itch severity and urticaria activity with dupilumab.

Phase 3 trials showed significant reductions in itch and urticaria severity with dupilumab compared to placebo at week 24. Dupilumab offers a new treatment option for CSU, being the first targeted ...